Pre-IPO Ab&B Bio-Tech (PHIP Updates) - Some Points Worth the Attention
Ab&B's performance has deteriorated due to product returns and inventory impairment.Intense competition/lacking R&D vision impact future...
493 Views
Ab&B Bio-Tech (中慧生物) Pre-IPO: PHIP Updates Suggest Competition Intensifying
China-based vaccine company Ab&B seeks to raise $100 million through Hong Kong listing. We look at the updates in PHIP and noted the intensified...
462 Views
Pre-IPO Ab&B Bio-Tech: Commercialization May Be Lower than Expected, Thereby Dragging Down Valuation
Vaccine companies need to bet on blockbuster varieties to scale up. Ab&B face commercialization uncertainty. Internationalization is the...
393 Views
Ab&B Bio-Tech (中慧生物) Pre-IPO: A Shaky Story of Flu Vaccine Rising Star
China's Ab&B seeks to raise $100 million through Hong Kong listing, but concerns arise over the potential of its flu vaccine product and the...
446 Views
Hong Kong: IPO SPOTLIGHT - OVERVIEW 2025
Hong Kong is the top global destination for IPOs in 2025, with over HK $280 billion raised so far. Large scale A+H dual listings have surged this...
573 Views